LB PHARMACEUTICALS INC

Historical 13F Holders

Symbol
LBRX
CUSIP
50180M108
All holders as of
Q2 2026
Type
Equity
Class
COM SHS
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 50180M108 since 12/18/2024, newest first.

Filer % of Class Filed
TCG Crossover GP II, LLC 13G/A Amendment 2
5.0% 8/14/2026
Event 6/30/2026
BlackRock, Inc. 13G/A Amendment 1 6.3% 7/29/2026
Event 6/30/2026
JPMorgan Chase & Co 13G 5.2% 7/16/2026
Event 6/30/2026
Commodore Capital LP 13G/A Amendment 2
6.8% 5/15/2026
Event 3/31/2026
Caligan Partners LP 13G
5.0% 5/15/2026
Event 3/31/2026
TCG Crossover GP II, LLC 13G/A Amendment 1
6.4% 5/15/2026
Event 3/31/2026
JPMorgan Chase & Co 13G/A Amendment 1 4.9% 5/13/2026
Event 3/31/2026
RA Capital Management, L.P. 13G/A Amendment 1
8.7% 2/17/2026
Event 12/31/2025
Deep Track Capital, LP 13D/A Amendment 1
11.7% 2/10/2026
Event 2/6/2025
BlackRock Portfolio Management LLC 13G/A Amendment 1 3.8% 1/21/2026
Event 12/31/2025
BlackRock, Inc. 13G 5.1% 1/21/2026
Event 12/31/2025
JPMorgan Chase & Co 13G 6.3% 1/21/2026
Event 12/31/2025
Trails Edge Capital Partners, LP 13G
5.0% 12/31/2025
Event 12/24/2025
BlackRock Portfolio Management LLC 13G 5.9% 10/17/2025
Event 9/30/2025
Pontifax Management 4 G.P. (2015) Ltd. 13D
6.3% 9/25/2025
Event 9/12/2025
RA Capital Management, L.P. 13G
7.5% 9/19/2025
Event 9/12/2025
Deep Track Capital, LP 13D
14.9% 9/19/2025
Event 9/12/2025
Commodore Capital LP 13G
5.5% 9/18/2025
Event 9/11/2025
TCG Crossover GP II, LLC 13G
7.8% 9/18/2025
Event 9/12/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 3 353 $13.5 k
2026 Q2 117 31.3 M $1.02 B
2026 Q1 78 28.3 M $694 M
2025 Q4 68 24.8 M $552 M
2025 Q3 54 21.0 M $331 M